Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

Rasim Gucalp5 sites in 1 country27 target enrollmentMay 2004

ConditionsNon-small Cell Lung Cancer

DrugsPS-341 (Velcade-drug)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Non-small Cell Lung Cancer
Sponsor: Rasim Gucalp
Enrollment: 27
Locations: 5
Primary Endpoint: Response rate
Status: Terminated
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.

Registry

clinicaltrials.gov

Start Date

May 2004

End Date

May 2007

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Rasim Gucalp

Responsible Party

Sponsor Investigator

Principal Investigator

Rasim Gucalp

Prof. Dept of Medicine (Oncology)

Montefiore Medical Center

Eligibility Criteria

Inclusion Criteria

•Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV.
•No prior chemotherapy regimen Patients must have adequate organ and marrow function